cycloheximide has been researched along with Myxoid Liposarcoma in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Albalat, R; Ron, D; Zinszner, H | 1 |
1 other study(ies) available for cycloheximide and Myxoid Liposarcoma
Article | Year |
---|---|
A novel effector domain from the RNA-binding protein TLS or EWS is required for oncogenic transformation by CHOP.
Topics: 3T3 Cells; Animals; Base Sequence; CCAAT-Enhancer-Binding Proteins; Cell Division; Cell Transformation, Neoplastic; Chromosome Aberrations; Cycloheximide; DNA Damage; DNA-Binding Proteins; Genetic Vectors; HeLa Cells; Heterogeneous Nuclear Ribonucleoprotein A1; Heterogeneous-Nuclear Ribonucleoprotein Group A-B; Heterogeneous-Nuclear Ribonucleoprotein Group C; Heterogeneous-Nuclear Ribonucleoproteins; Humans; Liposarcoma, Myxoid; Mice; Mice, Nude; Molecular Sequence Data; Mutagenesis, Insertional; Neoplasm Proteins; Nuclear Proteins; Oligodeoxyribonucleotides; Oncogenes; Recombinant Fusion Proteins; Ribonucleoproteins; RNA-Binding Protein EWS; RNA-Binding Protein FUS; RNA-Binding Proteins; Transcription Factor CHOP; Transcription Factors; Transplantation, Heterologous; Tumor Cells, Cultured | 1994 |